Investor Presentaiton

PRA1-5007 (Patient 1 of Cohort 2) - Efficacy Bone Marrow Blasts (%) Karnofsky Performance Score 90 80 70 70 70 100 TC BIOPHARM 11 10 8 6 4 2 0 Baseline D14 2.5 Per protocol, BM blasts measured only at baseline, D14, D28 and D100 Peripheral Blood Blasts (%) 2.0 1.5 1 1.0 5% 0.5 0.0 D14 D28 D49 D70 D28 BASELINE DAY O DAY 14 DAY 28 DAY 49 DAY 70 300 250 Platelets (x109/L) 200 50 བྷྱཿ ཤྩ ༔ ྴ ཎྜ ྴ ° 150 100 Baseline DO 40 D3 07 D14 D28 D49 D70 Healthy range values: 150-400x10^9/L Neutrophils (x109/L) 2.0 1.8 1.5 1.3 1.0 0.8 0.5 0.3 0.0 Baseline DO DZ D14 D28 D49 D70 Healthy range values: 1-7x10^9/L This patient achieved complete remission (CR) by Day 28 following a single infusion of TCB002, defined as Bone Marrow blasts <5%, Peripheral Blood Blasts 0%, and neutrophil and platelet recovery Baseline DO 07 • • PRA1-5007 has received three doses of TCB-002 (Day 0, Day 36 and Day 79) Performance status at Day 70, following two infusions with TCB002, reached the maximum score of KPS 100 21

View entire presentation